Gupta Nupur, Delrow Jeffrey, Drawid Amar, Sengupta Anirvan M, Fan Gaofeng, Gélinas Céline
Center for Advanced Biotechnology and Medicine, Robert Wood Johnson Medical School, Rutgers University, Piscataway, New Jersey, USA.
Cancer Res. 2008 Feb 1;68(3):808-14. doi: 10.1158/0008-5472.CAN-07-3169.
Persistent Rel/nuclear factor-kappaB (NF-kappaB) activity is a hallmark of many human cancers, and the Rel proteins are implicated in leukemia/lymphomagenesis but the mechanism is not fully understood. Microarray analysis to identify transformation-impacting genes regulated by NF-kappaB's oncogenic v-Rel and c-Rel proteins uncovered that Rel protein expression leads to transcriptional repression of key B-cell receptor (BCR) components and signaling molecules like B-cell linker (BLNK), the B-cell adaptor for phosphoinositide 3-kinase (BCAP) and immunoglobulin lambda light chain (Ig lambda), and is accompanied by a block in BCR-mediated activation of extracellular signal-regulated kinase, Akt, and c-Jun-NH(2)-kinase in response to anti-IgM. The BLNK and BCAP proteins were also down-regulated in lymphoid cells expressing a transformation-competent chimeric RelA/v-Rel protein, suggesting a correlation with the capacity of Rel proteins to transform lymphocytes. DNA-binding studies identified functional NF-kappaB-binding sites, and chromatin immunoprecipitation (ChIP) data showed binding of Rel to the endogenous blnk and bcap promoters in vivo. Importantly, restoration of either BLNK or BCAP expression strongly inhibited transformation of primary chicken lymphocytes by the potent NF-kappaB oncoprotein v-Rel. These findings are interesting because blnk and other BCR components and signaling molecules are down-regulated in primary mediastinal large B-cell lymphomas and Hodgkin's lymphomas, which depend on c-Rel for survival, and are consistent with the tumor suppressor function of BLNK. Overall, our results indicate that down-regulation of BLNK and BCAP is an important contributing factor to the malignant transformation of lymphocytes by Rel and suggest that gene repression may be as important as transcriptional activation for Rel's transforming activity.
持续的Rel/核因子κB(NF-κB)活性是许多人类癌症的一个标志,Rel蛋白与白血病/淋巴瘤的发生有关,但其机制尚未完全清楚。通过微阵列分析来鉴定受NF-κB致癌性v-Rel和c-Rel蛋白调控的影响转化的基因,结果发现Rel蛋白表达导致关键B细胞受体(BCR)组分以及诸如B细胞连接蛋白(BLNK)、磷酸肌醇3激酶的B细胞衔接蛋白(BCAP)和免疫球蛋白λ轻链(Igλ)等信号分子的转录抑制,并伴随着BCR介导的细胞外信号调节激酶、Akt和c-Jun氨基末端激酶对抗IgM反应的激活受阻。在表达具有转化能力的嵌合RelA/v-Rel蛋白的淋巴细胞中,BLNK和BCAP蛋白也下调,这表明与Rel蛋白转化淋巴细胞的能力相关。DNA结合研究鉴定出功能性NF-κB结合位点,染色质免疫沉淀(ChIP)数据显示Rel在体内与内源性blnk和bcap启动子结合。重要的是,BLNK或BCAP表达的恢复强烈抑制了由强效NF-κB癌蛋白v-Rel引起的原代鸡淋巴细胞的转化。这些发现很有趣,因为在原发性纵隔大B细胞淋巴瘤和霍奇金淋巴瘤中,blnk和其他BCR组分及信号分子下调,这些肿瘤依赖c-Rel存活,这与BLNK的肿瘤抑制功能一致。总体而言,我们的结果表明,BLNK和BCAP的下调是Rel导致淋巴细胞恶性转化的一个重要因素,并表明基因抑制对于Rel的转化活性可能与转录激活同样重要。